Table 4.
Cancer-specific and all-cause survival by category of comorbidity among those with Stage I-III disease
| Cancer-specific mortality Hazard Ratios (95% CI) | |||
|---|---|---|---|
| Impact of comorbidity evaluated at C3 Score of:* | Unadjusted | Model 11 | Model 22 |
| 0 | 1.00 | 1.00 | 1.00 |
| 1 | 1.38 (1.11-1.71) | 1.33 (1.04-1.71) | 1.24 (0.96-1.6) |
| 2 | 1.68 (1.2-2.36) | 1.56 (1.05-2.31) | 1.36 (0.91-2.04) |
| 3 | 1.86 (1.26-2.74) | 1.62 (1.03-2.54) | 1.34 (0.84-2.13) |
| 6 | 1.68 (1.08-2.61) | 1.15 (0.71-1.87) | 0.85 (0.51-1.4) |
| All-cause mortality Hazard Ratios (95% CI) | |||
| C3 score* | Unadjusted | Model 11 | Model 22 |
| 0 | 1.00 | 1.00 | 1.00 |
| 1 | 1.30 (1.06-1.6) | 1.25 (0.99-1.58) | 1.17 (0.92-1.48) |
| 2 | 1.57 (1.14-2.17) | 1.43 (0.99-2.07) | 1.27 (0.87-1.85) |
| 3 | 1.77 (1.23-2.56) | 1.54 (1.01-2.35) | 1.28 (0.83-1.99) |
| 6 | 1.97 (1.33-2.9) | 1.44 (0.93-2.23) | 1.04 (0.66-1.63) |
1Adjusted for age, sex, site, stage, ethnicity, deprivation and rurality 2 Adjusted for all previous variables plus receipt of treatment. * evaluation of the OR at a score of 1, 2, 3 and 6 (in relation to a score of 0). No results are presented beyond 6 as the 95th percentile of the C3 Index score distribution was 6.74, which means estimates of the OR beyond this point on the scale are of limited utility.